Concomitant administration of sodium 2,3-dimercapto-1-propanesulphonate (DMPS) and diphenyl diselenide reduces effectiveness of DMPS in restoring damage induced by mercuric chloride in mice.
The effect of combined therapy with diphenyl diselenide (PhSe)(2) and sodium 2,3-dimercapto-propane-1-sulphonate (DMPS) against alterations induced by mercury (Hg(2+)) was evaluated. Mice were exposed to mercuric chloride (HgCl(2)) (1mg/kg, subcutaneously) for two weeks. After that, mice received (PhSe)(2) (15.6 mg/kg), or DMPS (12.6 mg/kg), or a combination of both for one week. Thiobarbituric acid-reactive substances (TBARS), ascorbic acid and Hg(2+) levels and glutathione S-transferase (GST) and catalase (CAT) activities were carried out in kidney. Hematological parameters, plasmatic bilirubin, uric acid, urea and creatinine levels as well as lactate dehydrogenase (LDH) activity were determined. (PhSe)(2) or DMPS restored the increase in LDH activity and TBARS, bilirubin, uric acid, urea and creatinine levels caused by HgCl(2). The levels of erythrocytes, hemoglobin and hematocrit reduced by HgCl(2) exposure were restored by (PhSe)(2) or DMPS administration in mice. Leukocyte and platelet counts modified by HgCl(2) exposure were restored by (PhSe)(2) or DMPS therapy. DMPS restored the increase in Hg(2+) levels induced by exposure to HgCl(2). Concomitant administration of (PhSe)(2) and DMPS reduced the effectiveness of DMPS in restoring damage induced by HgCl(2). Combined therapy with (PhSe)(2) and DMPS was less effective than isolated therapies in restoring the damage induced by HgCl(2) in mice.
Brandão
Ricardo
R
Departamento de Quimica, Centro de Ciencias Naturais e Exatas, Universidade Federal de Santa Maria, Santa Maria CEP 97105-900, RS, Brazil.
Borges
Lysandro Pinto
LP
Nogueira
Cristina Wayne
CW
D000818:Animals; D000975:Antioxidants / Q000378:metabolism; D001205:Ascorbic Acid / Q000378:metabolism; D001555:Benzene Derivatives / Q000494:pharmacology*; D001663:Bilirubin / Q000378:metabolism; D001772:Blood Cell Count; D002374:Catalase / Q000378:metabolism; D002614:Chelating Agents / Q000494:pharmacology*; D003404:Creatinine / Q000378:metabolism; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005982:Glutathione Transferase / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D007958:Leukocyte Count; D008214:Lymphocytes / Q000187:drug effects; D008297:Male; D008627:Mercuric Chloride / Q000037:antagonists & inhibitors* / Q000493:pharmacokinetics / Q000633:toxicity*; D051379:Mice; D009000:Monocytes / Q000187:drug effects; D009504:Neutrophils / Q000187:drug effects; D016566:Organoselenium Compounds / Q000494:pharmacology*; D010976:Platelet Count; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014494:Unithiol / Q000494:pharmacology*; D014527:Uric Acid / Q000378:metabolism
D000975:Antioxidants; D001555:Benzene Derivatives; D002614:Chelating Agents; D006454:Hemoglobins; D016566:Organoselenium Compounds; D017392:Thiobarbituric Acid Reactive Substances; C061132:diphenyldiselenide; D014527:Uric Acid; D014494:Unithiol; D008627:Mercuric Chloride; D003404:Creatinine; D002374:Catalase; D005982:Glutathione Transferase; D001205:Ascorbic Acid; D001663:Bilirubin